Principal Clinical Scientist
Invivyd, Inc.
Waltham, MA, United States
Anna Holmes is a principal clinical scientist at Invivyd, where she has overseen development of the monoclonal antibodies pemivibart and adintrevimab for prophylaxis of COVID-19 across Phase 1-3 trials since 2021. Prior to her time at Invivyd, Anna worked in both clinical research and medical affairs roles at Galderma Laboratories. Anna received her PhD in microbiology and immunology from the University of North Carolina at Chapel Hill in 2008.
Disclosure(s): Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)
91 - Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart
Thursday, October 17, 2024
11:18 AM – 11:30 AM US PT